癌细胞通常具有代谢适应性，有利于它们的生长、侵袭和转移。因此，内部细胞能量代谢的重新编程目前是癌症研究领域的热点之一。虽然有氧酵解（也称为华伯克效应）长期以来被认为是癌细胞能量代谢的主要形式，但新兴证据表明其他代谢形式，尤其是氧化磷酸化（OXPHOS），可能在某些类型的癌症中起到至关重要的作用。值得注意的是，代谢综合征（MetS）女性，包括肥胖、高血糖、血脂异常和高血压，患上子宫内膜癌（EC）的风险增加，表明代谢和EC有密切联系。有趣的是，EC细胞类型中的代谢偏好有所不同，特别是癌干细胞和化疗耐药细胞。目前，普遍认为在EC细胞中，酵解是主要的能量供应者，而OXPHOS则减少或受损。此外，针对酵解和/或OXPHOS途径的特定药物可以抑制肿瘤细胞生长并促进化疗敏感性。例如，二甲双胍和控制体重不仅可以降低EC的发病率，还可以改善EC患者的预后。在本综述中，我们全面概述了代谢与EC之间关系的当前深入理解，并提供关于针对能量代谢的新疗法开发的最新见解，以作为辅助治疗与化疗结合使用，特别是针对对传统化疗耐药的EC患者。版权所有© 2023年作者。由Elsevier Masson SAS出版。保留所有权利。

Cancer cells are usually featured by metabolic adaptations that facilitate their growth, invasion, and metastasis. Thus, reprogramming of intracellular energy metabolism is currently one of the hotspots in the field of cancer research. Whereas aerobic glycolysis (known as the Warburg effect) has long been considered a dominant form of energy metabolism in cancer cells, emerging evidence indicates that other metabolic forms, especially oxidative phosphorylation (OXPHOS), may play a critical role at least in some types of cancer. Of note, women with metabolic syndromes (MetS), including obesity, hyperglycemia, dyslipidemia, and hypertension, have an increased risk of developing endometrial carcinoma (EC), suggesting a close link between metabolism and EC. Interestingly, the metabolic preferences vary among EC cell types, particularly cancer stem cells and chemotherapy-resistant cells. Currently, it is commonly accepted that glycolysis is the main energy provider in EC cells, while OXPHOS is reduced or impaired. Moreover, agents specifically targeting the glycolysis and/or OXPHOS pathways can inhibit tumor cell growth and promote chemosensitization. For example, metformin and weight control not only reduce the incidence of EC but also improve the prognosis of EC patients. In this review, we comprehensively overview the current in-depth understanding of the relationship between metabolism and EC and provide up-to-date insights into the development of novel therapies targeting energy metabolism for auxiliary treatment in combination with chemotherapy for EC, especially those resistant to conventional chemotherapy.Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.